Publications by authors named "A Bertaut"
Purpose: A phase I study of FOLFIRINOX3-bevacizumab (bFOLFIRINOX3)defined the RP2D for irinotecan at 70 mg/m² and showed promising activity. This phase II trial aimed to evaluate the efficacy of bFOLFIRINOX-3 in chemorefractory metastatic colorectal cancer (mCRC).
Methods: In phase II, chemorefractory mCRC were enrolled.
In the tumour microenvironment, IL-1α promotes neoangiogenesis, matrix remodelling, tumour proliferation, chemoresistance, and metastases. Highly expressed in human colorectal cancers, IL-1α is associated with poor prognosis. XB2001, a fully human monoclonal antibody neutralizing IL-1α, was evaluated for safety and preliminary efficacy with trifluridine/tipiracil (FTD/TPI) and bevacizumab in metastatic colorectal cancer patients previously treated with oxaliplatin- and irinotecan-based chemotherapies.
View Article and Find Full Text PDFArticle Synopsis
- Patients with high-risk hormone receptor-positive, HER2-negative breast cancer (HR+ BC) show a significant risk of relapse, prompting the need for additional treatment strategies.
- The study analyzed data from the CANcer TOxicities (CANTO) study, involving patients between 2012 and 2022, categorizing them based on various unfavorable features indicating high risk.
- Results indicated that most patients underwent (neo)adjuvant chemotherapy and endocrine therapy; however, many discontinued treatment due to adverse events, with a 5-year survival rate reflecting the need for ongoing management in this patient group.
Objective: This study aimed to determine the predictive factors for analgesic reduction and amelioration of mobility following percutaneous sacroplasty in patients with insufficiency fractures or metastatic lesions.
Methods: A single-center retrospective analysis of 49 patients who underwent percutaneous sacroplasty for insufficiency fractures and sacral pathological lesions was conducted. Visual analog scale (VAS), Functional Mobility Scale (FMS), and Oswestry Disability Index (ODI) were assessed.
Trifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC refractory to standard chemotherapy. This multicenter, randomized, double blind, non-comparative Phase I-II study (ClinicalTrials.
View Article and Find Full Text PDF